| |
|
|
|
|
|
|
|||
|
Blood, 1 April 2007, Vol. 109, No. 7, pp. 3080-3083. Prepublished online as a Blood First Edition Paper on December 14, 2006; DOI 10.1182/blood-2006-06-031096.
NEOPLASIA Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 2 Statistical Center, Southwest Oncology Group, Seattle, WA; 3 Division of Pathology, City of Hope National Medical Center, Duarte, CA; 4 Department of Pathology, University of New Mexico School of Medicine, Albuquerque; 5 Medicine/Hematology University of Texas, Health Science Center at San Antonio We compared the gene expression profile of adult acute lymphoblastic leukemia (ALL) to normal hematopoietic and non-ALL samples using oligonucleotide arrays. Connective tissue growth factor (CTGF) was the highest overexpressed gene in B-cell ALL compared with the other groups, and displayed heterogeneous expression, suggesting it might have prognostic relevance. CTGF expression was examined by quantitative reverse transcriptasepolymerase chain reaction (QRT-PCR) on 79 adult ALL specimens. CTGF expression levels were significantly increased in ALL cases with B-lineage (P < .001), unfavorable cytogenetics (P < .001), and blasts expressing CD34 (P < .001). In a multivariate proportional hazards model, higher CTGF expression levels corresponded to worsening of overall survival (OS; hazard ratio 1.36, for each 10-fold increase in expression; P = .019). Further studies are ongoing to confirm the prognostic value of CTGF expression in ALL and to investigate its role in normal and abnormal lymphocyte biology.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||